Medgenics Share Discussion Threads

[count chris] 16/7/2013 18:13

If it means a bounce to £9 I'd rather see 190p ;)

[jammytass] 16/7/2013 17:59

on the up usa last 5 days so 320 on cards soon

[buywell2] 16/7/2013 17:53

For the attention of jimmytass ..... XEN poster about MEDU

[237gmoney] 15/7/2013 13:02

The latest Webcast from the JMP Healthcare presentation is now available via the Medgenics website

www.medgenics.com

or you can access the webcast here

hxxp://wsw.com/webcast/jmp21/MDGN/

In summary;

Over $30m in the bank currently and spending about $1m a month

Potential near term value creating milestones with US Clinical trials starting very shortly in Q4 - Expect announcement to made soon

[237gmoney] 09/7/2013 14:35

Great news today before the company present at the JMP Healthcare conference tomorrow. Not much has happened over tha last month and hopefully this is the start of more positive newsflow.

Still awaiting news of the US Clinical trials so a JV or partnership deal should be announced shortly. Looking forward to the presentation tomorrow as well for an update on recent progress.

Medgenics Inc $1.9 Million Grant Awarded from the Israeli OCS

RNS Number : 8940I
Medgenics Inc
09 July 2013

Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.

The grant will be used to cover R&D expenses for the 12-month period from December 2012 through November 2013 to support further research and clinical development of the Company's proprietary tissue-based Biopump(TM) platform technology with respect to the treatment of anemia and hepatitis.
The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company's business including financial position, R&D capabilities and management experience.

Under the terms of the OCS grant, MMI will repay the grant in full, plus interest, through royalties on revenue received from commercializing the developed technology. The payment of royalties is contingent on such revenues and, in the absence of such revenues, no royalty payments to the OCS are required.

"We are delighted to have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. This is our seventh consecutive grant from the Israeli OCS. These grants have been instrumental in furthering the development of our technology and support us in advancing our clinical trials in the United States and Israel," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics.

[237gmoney] 07/6/2013 09:01

Another interview with our CEO...

The next big thing in the way that we fight chronic diseases.

hxxp://www.nbtequitiesresearch.com/video/nbt-medgenics-1

[237gmoney] 06/6/2013 08:56

The COO bought shares this week in the US. Not many but maybe the start of some director buying. There have been more buys than sells in the last two weeks over the water but the opposite here. Also Issac Blech was in China recently on behalf of Medgenics looking at building some relationships. Perhaps new contracts for the biopumps on the cards. Hoping to hear news soon of when the US clinical trails will start and should have some more interest here after that.

[237gmoney] 31/5/2013 09:26

A recent interview with our CEO.

http://stocknewsnow.com/andrew-pearlman-phd-president-ceo-of-medgenics-inc-biopump-platform-technology-that-delivers-patient-produced-protein-therapy/

[jammytass] 23/5/2013 19:02

dont forget the baxters deal is dead new cmpys and major bod buying needed here

[237gmoney] 23/5/2013 10:46

A couple of buys today which is interesting after a week or so of nothing. Now that the extra employees shares have been given the ok after the AGM and added to the pot, the company and all the directors are set up now make money from a rising share price.

Last year the company announced a deal for the Biopumps in the first week of June and pretty soon they should announce a tie up with another company for the US Clinical trails. Hopefully it will all soon fall into place.

Looking forward to those 'value enhancing milestones'...

[jammytass] 17/5/2013 05:22

buy well> good point also baxters have not signed any new deal with medgenics but hold 2% of xen both cmpys could be massive

[237gmoney] 15/5/2013 16:24

Yes fair point BW. Medgenics have a bit further to go hence why the stock is where it is. But if Medgenics can get through stage two and three the end game will show a completely different picture to XEN.

[buywell2] 15/5/2013 15:14

237gmoney

You do not address the fact that XEN are now in stage 3 trials

Thus the chance of any failure is very remote especially as this is a reformulated drug by XEN with a new XEN delivery technology.

Have you any idea how much it costs to get a drug through Phase 1 , 2 and 3 clinical trials ?

[237gmoney] 15/5/2013 14:38

Jammy, it certainly seems that way - up three days in a row now in the US and the US graph seems to be showing a turn around since the Needham Healthcare Conference.

When news of a JV partner does come through for the US trials I expect this to jump up on the news. They hope to start the trails in the 2nd half of the year so I expect more news in June on this.

And June has traditionally been quite a good month here if you look back over the years....

[jammytass] 14/5/2013 19:32

some good posts guys now is the time to top up now at 294 major rises will be on the cards!!!!!!

[237gmoney] 14/5/2013 16:27

Buywell, thanks for posting this.

However, given a choice of once a month or once every 3-6 months and potentially longer, which would you choose? I think many would choose the latter.

Medgenics have already proved this.

Don't get me wrong, Xenetic's once a month is much better than what is currently out there but Medgenics take it up another level from that.

Does Xenetic's haemoglobin levels maintain the required 10-12 limits according to the US FDA standards continuously for 1 month? Medgenics have so far proven >6 months in one patient from one dose.

[buywell2] 14/5/2013 15:32

Re erythropoietin being used once a month instead of 2 or 3 times a week , this company seem well advanced




Xenetic Biosciences PLC Commencement of dosing in Phase III study


09 May 2013



Phase III study commences with dosing of first patient for ErepoXen(TM)

Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that as part of its Russian Phase III study of ErepoXen(TM), its novel therapy for the treatment of anaemia, its co-development partner SynBio LLC has dosed the first patient.

ErepoXen(TM) is Xenetic's polysialylated erythropoietin (PSA-EPO) candidate for the treatment of patients with chronic anaemia, a decrease in the number of red blood cells (RBCs) or less than the normal quantity of haemoglobin in the blood. EPO is a hormone produced by the kidneys that controls the production of RBCs. Anaemia leads to hypoxia (a lack of oxygen) in organs because haemoglobin, found inside RBCs, normally carries oxygen from the lungs to the tissues and, since all human cells depend on oxygen for survival, this can have a wide range of clinical consequences. EPO stimulates the production of RBCs and as a result is the treatment of choice for affected patients.

In the case of End Stage Renal Disease (ESRD) patients, EPO is administered intravenously three times per week. Based on the subcutaneous method of administration, Xenetic's ErepoXen(TM) has already demonstrated in over 100 subjects in Phase I and II(a) clinical trials that it has the potential to be a long-acting version, with a likely dosing profile of once per month.

This 24-month Phase III study in Russia comprises of an open-label, comparative, ten (10) centre, randomised study to assess the efficacy, safety and tolerance of ErepoXen(TM) in the correction of anaemia and maintenance of the haemoglobin levels in chronic kidney disease EPO-naïve patients (i.e. those not previously administered with EPO) who are not on dialysis.

The study will involve treatment periods of 24 weeks for 150 male and female patients between 18-75 years of age with established Stage 3 or 4 chronic kidney disease not currently requiring dialysis.

The primary objective of the Phase III study is to confirm the therapeutic efficacy of ErepoXen(TM) in anaemia correction by achieving the hemoglobin level of >=100 g/L in comparison with Aranesp(R), which is the current market leading therapy. According to a recent report from Evaluate Group, Aranesp(R) recorded global sales of approximately US$2.0B in 2012. Total EPO sales in Russia are estimated to be circa US$140M per annum.

Scott Maguire, CEO of Xenetic Biosciences said: "With the commencement of this Phase III trial in Russia, ErepoXen(TM) is now the most advanced candidate in our portfolio, and with our double-digit royalty agreement with SynBio, we can now see the potential of a recurring revenue stream. We look forward to providing our shareholders with further news on ErepoXen(TM) as such news develops."

[237gmoney] 14/5/2013 15:15

Harold, I do not know the exact cost of the technology but what I gather from my research and listening to the recent presentation at the Roth conference, is that this technology is very cost effective. In fact that is the whole point of the technology. It will be cheaper for patients, doctors and everyone involved. The technology can be transported very easily and to anywhere in the world (or where ever Fedex or DHS or the like deliver) and give the same results.

I expect this technology to change the whole medical landscape for this type of medicine and once this has been given US FDA approval, the company will most likely be taken out by the highest bidder.

I agree with PDT but I expect £6 sooner once a deal is confirmed with a US partner. The technology has now been proven that it works on humans and although results may differ slightly based on the dosage given, each and every person that takes the drug will ultimately find that it works for them for much longer than they currently experience.

This is why this stock is a no brainer. Just these things take time.

[pdt] 13/5/2013 20:23

I bought a few more today. At some point over the next six months there will be news on a trial partner or joint venture partner. When that happens you will not be able to get any shares at a reasonable price. Since my timing is rubbish I am happy to add in a quiet period. My personal short term target is £6 by the end of the year. No clever analysis they will just be chased higher.

[haroldthegreat] 13/5/2013 12:06

sorry dont have 30 mins to spare to look at it. what does it say about cost compared with drug? will it be cheaper or the same ? if its more then in the real world nobody will want to pay.

[237gmoney] 13/5/2013 11:59

Haven't had a chance to totally review the 1st quarter results but we still over $36m in the bank now so more than enough to see us through the US clinical trials.

There should be some value enhancing milestones according to the reports and a partner for the US clinical trials would be one of those. I expect that to come out in the next month or so.

[237gmoney] 30/4/2013 11:55

Harold, not sure if the link below has some of the answers to your questions

Webcast - Roth Conference Presentation - 18th March 2013 - 30mins long


Will most likely be the same presentation given at the Needham healthcare conference later today in New York. AGM also today so likely to be an update on current prospects?

A couple of buys here today and the stock has increased a small bit in the US over the last week so will hopefully see this pick up in May. The annual report did say there have been a couple of companies interested in joining up for the US Clinical trials later this year so I expect some progress to made with this and an announcement soon which will boost the Share price.

[haroldthegreat] 25/4/2013 15:32

the pump lasted 2-4 months. the question is whats the cost of the pump compared with the drug. the other advantage is the blood level is maintained at the optimum level as opposed to a massive high level declining to sub optimal level. why does the pump stop producing?

[237gmoney] 25/4/2013 15:22

Great news out today on the CKD interim results. Pretty much as expected but will boost the company before the Presentation and AGM next week.

Should see more interest in this one in the coming weeks with a full scale US Trial penciled in to start in the 2nd half of 2013.